Literature DB >> 31044349

Response to 'Comment on "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States"'.

Holly Guy1, Lydia Walder2, Mark Fisher2.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31044349     DOI： 10.1007/s40273-019-00803-7

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  4 in total

1.  Comment on "Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States".

Authors:  R Brett McQueen; Melanie D Whittington; Rick H Chapman; Varun M Kumar; Jonathan D Campbell
Journal:  Pharmacoeconomics       Date:  2019-07       Impact factor: 4.981

2.  Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial.

Authors:  Jonathan A Ledermann; Philipp Harter; Charlie Gourley; Michael Friedlander; Ignace Vergote; Gordon Rustin; Clare Scott; Werner Meier; Ronnie Shapira-Frommer; Tamar Safra; Daniela Matei; Anitra Fielding; Stuart Spencer; Philip Rowe; Elizabeth Lowe; Darren Hodgson; Mika A Sovak; Ursula Matulonis
Journal:  Lancet Oncol       Date:  2016-09-09       Impact factor: 41.316

3.  Cost-Effectiveness of Niraparib Versus Routine Surveillance, Olaparib and Rucaparib for the Maintenance Treatment of Patients with Ovarian Cancer in the United States.

Authors:  Holly Guy; Lydia Walder; Mark Fisher
Journal:  Pharmacoeconomics       Date:  2019-03       Impact factor: 4.981

4.  Olaparib maintenance therapy in patients with platinum-sensitive relapsed serous ovarian cancer: a preplanned retrospective analysis of outcomes by BRCA status in a randomised phase 2 trial.

Authors:  Jonathan Ledermann; Philipp Harter; Charlie Gourley; Michael Friedlander; Ignace Vergote; Gordon Rustin; Clare L Scott; Werner Meier; Ronnie Shapira-Frommer; Tamar Safra; Daniela Matei; Anitra Fielding; Stuart Spencer; Brian Dougherty; Maria Orr; Darren Hodgson; J Carl Barrett; Ursula Matulonis
Journal:  Lancet Oncol       Date:  2014-05-31       Impact factor: 41.316
  4 in total
  2 in total

1.  Cost comparison of adverse event management among breast and ovarian cancer patients treated with poly (ADP-ribose) polymerase inhibitors: analysis based on phase 3 clinical trials.

Authors:  Lin Fan; Yuanyuan Zhang; Peter Maguire; Dominic Muston; Matthew Monberg; Jagadeswara Rao Earla; Adela Mihai; Poonam Gulati
Journal:  J Mark Access Health Policy       Date:  2022-06-08

2.  Cost-effectiveness of olaparib, a PARP inhibitor, for patients with metastatic castration-resistant prostate cancer in China and United States.

Authors:  Chenxia Xu; Jiaqin Cai; Jie Zhuang; Bin Zheng; Li Chen; Hong Sun; Guiyan Zheng; Xiaoxia Wei; Maobai Liu
Journal:  Ann Transl Med       Date:  2022-08
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.